Modern Oncological Approaches to Gastric Adenocarcinoma

Gastroenterology Clinics of North America

Volumn 42, Issue 2, 2013, Pages 359-369

  Wadhwa, Roopma ^a   Taketa, Takashi ^a   Sudo, Kazuki ^a   Blum, Mariela A ^a   Ajani, Jaffer A ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Adjuvant therapy; Chemoradiation; Gastric adenocarcinoma; Gastric cancer; Multidisciplinary approach; Perioperative

Indexed keywords

5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; BEVACIZUMAB; CAPECITABINE; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; DOVITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; EVEROLIMUS; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FLUOROPYRIMIDINE; FLUOROURACIL; FORETINIB; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; ONARTUZUMAB; OXALIPLATIN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PLATINUM DERIVATIVE; PROTEIN KINASE B; RILOTUMUMAB; SCATTER FACTOR RECEPTOR; TAXANE DERIVATIVE; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNINDEXED DRUG;

ADJUVANT CHEMORADIOTHERAPY; ADJUVANT THERAPY; ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; FGFR GENE; GATA4 GENE; GATA6 GENE; HUMAN; KLF5 GENE; MULTIPLE CYCLE TREATMENT; ONCOGENE; PROTEIN EXPRESSION; REVIEW; STOMACH ADENOCARCINOMA; STOMACH CANCER;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY, ADJUVANT; CHEMOTHERAPY, ADJUVANT; GASTRECTOMY; HUMANS; MOLECULAR TARGETED THERAPY; NEOADJUVANT THERAPY; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84877021935     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2013.01.011     Document Type: Review

References (37)

1. Siegel R., Ward E., Brawley O., et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011, 61(4):212-236. Available at:, Accessed November 19, 2012. http://www.ncbi.nlm.nih.gov/pubmed/21685461, 10.3322/caac.20121.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62(1):10-29. Available at:, Accessed November 19, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22237781, 10.3322/caac.20138.
3. Ajani J.A., Barthel J.S., Bekaii-Saab T., et al. Gastric cancer. J Natl Compr Canc Netw 2010, 8(4):378-409. Available at:, Accessed October 24, 2012. http://www.jnccn.org/content/8/4/378.long.
4. Rohatgi P.R., Mansfield P.F., Crane C.H., et al. Surgical pathology stage by American Joint Commission on Cancer criteria predicts patient survival after preoperative chemoradiation for localized gastric carcinoma. Cancer 2006, 107(7):1475-1482. Available at:, Accessed October 23, 2012. http://www.ncbi.nlm.nih.gov/pubmed/16944539.
5. Stephens M.R., Lewis W.G., Brewster A.E., et al. Multidisciplinary team management is associated with improved outcomes after surgery for esophageal cancer. Dis Esophagus 2006, 19(3):164-171. Available at:, Accessed November 12, 2012. http://www.ncbi.nlm.nih.gov/pubmed/16722993, 10.1111/j.1442-2050.2006.00559.x.
6. Suzuki A., Xiao L., Taketa T., et al. Localized gastric cancer treated with chemoradation without surgery: UTMD Anderson Cancer Center experience. Oncology 2012, 82(6):347-351. Available at:. http://www.ncbi.nlm.nih.gov/pubmed/22677933, 10.1159/000338318 000338318.
7. Macdonald J.S., Smalley S.R., Benedetti J., et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001, 345(10):725-730. Available at:, Accessed October 10, 2012. http://www.ncbi.nlm.nih.gov/pubmed/11547741.
8. Smalley S.R., Benedetti J.K., Haller D.G., et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 2012, 30(19):2327-2333. Available at:, Accessed November 12, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22585691, 10.1200/jco.2011.36.7136.
9. Fuchs C.S., Tepper J.E., Niedzwiecki D., et al. Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction adenocarcinoma using epirubicin, cisplatin, infusional fluourouracil before and after infusional fluorouracil and radiotherapy compared with bolus fluorouracil/leucovorin before and after chemoradiation. Intergroup trial CALGC 80101. J Clin Oncol 2011, 29. [abstract no. 4003].
10. Kim S., Lim D.H., Lee J., et al. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys 2005, 63(5):1279-1285. Available at:, Accessed November 15, 2012. http://www.ncbi.nlm.nih.gov/pubmed/16099596, 10.1016/j.ijrobp.2005.05.005.
11. Lee J., Lim do H., Kim S., et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST rial. J Clin Oncol 2012, 30(3):268-273. Available at:, Accessed November 1, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22184384, 10.1200/JCO.2011.39.1953.
12. Yao J.C., Ajani J.A. Gastric cancer. Curr Opin Gastroenterol 2000, 16(6):516-521. Available at:, Accessed October 23, 2012. http://www.ncbi.nlm.nih.gov/pubmed/17031130.
13. Sakuramoto S., Sasako M., Yamaguchi T., et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007, 357(18):1810-1820. Available at:, Accessed November 12, 2012. http://www.ncbi.nlm.nih.gov/pubmed/17978289.
14. Sasako M., Sakuramoto S., Katai H., et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011, 29(33):4387-4393. Available at:, Accessed December 1, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22010012, 10.1200/JCO.2011.36.5908.
15. Bang Y.J., Kim Y.W., Yang H.K., et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012, Available at:, Accessed October 2, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22226517, 10.1016/S0140-6736(11)61873-4.
16. Paoletti X., Oba K., Burzykowski T., et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 2010, 303(17):1729-1737. Available at:, Accessed November 12, 2012. http://www.ncbi.nlm.nih.gov/pubmed/20442389, 10.1001/jama.2010.534.
17. Cunningham D., Allum W.H., Stenning S.P., et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006, 355(1):11-20.
18. Ychou M., Boige V., Pignon J.P., et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011, 29(13):1715-1721. Available at:, Accessed November 12, 2012. http://jco.ascopubs.org/content/29/13/1715.full.pdf, 10.1200/JCO.2010.33.0597.
19. Dikken J.L., van Sandick J.W., Maurits Swellengrebel H.A., et al. Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). BMC Cancer 2011, 11:329. Available at:, Accessed October 2, 2012. http://www.biomedcentral.com/1471-2407/11/329, 10.1186/1471-2407-11-329.
20. Van Cutsem E., Moiseyenko V.M., Tjulandin S., et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006, 24(31):4991-4997. Available at:, Accessed November 19, 2012. http://www.ncbi.nlm.nih.gov/pubmed/17075117.
21. Koizumi W., Narahara H., Hara T., et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008, 9(3):215-221. Available at:, Accessed November 20, 2012. http://www.ncbi.nlm.nih.gov/pubmed/18282805.
22. Bang Y.J., Van Cutsem E., Feyereislova A., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376(9742):687-697. Available at:, Accessed October 2, 2012. http://www.ncbi.nlm.nih.gov/pubmed/20728210, 10.1016/S0140-6736(10)61121-X.
23. Grabsch H., Sivakumar S., Gray S., et al. HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series. Cell Oncol 2010, 32(1-2):57-65. 10.3233/clo-2009-0497.
24. Gravalos C., Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008, 19(9):1523-1529. 10.1093/annonc/mdn169.
25. Warneke V.S., Behrens H.M., Boger C., et al. Her2/neu testing in gastric cancer: evaluating the risk of sampling errors. Ann Oncol 2012, Available at:, Accessed November 28, 2012. http://www.ncbi.nlm.nih.gov/pubmed/23139264, 10.1093/annonc/mds528.
26. Wu Y., Grabsch H., Ivanova T., et al. Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer. Gut 2012, Available at:, Accessed October 23, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22735568, 10.1136/gutjnl-2011-301373.
27. Lennerz J.K., Kwak E.L., Ackerman A., et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 2011, 29(36):4803-4810. 10.1200/jco.2011.35.4928.
28. Lee J., Seo J.W., Jun H.J., et al. Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. Oncol Rep 2011, 25(6):1517-1524. 10.3892/or.2011.1219.
29. Graziano F., Galluccio N., Lorenzini P., et al. Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. J Clin Oncol 2011, 29(36):4789-4795. 10.1200/jco.2011.36.7706.
30. Smolen G.A., Sordella R., Muir B., et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A 2006, 103(7):2316-2321. 10.1073/pnas.0508776103.
31. Kataoka Y., Mukohara T., Tomioka H., et al. Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks. Invest New Drugs 2012, 30(4):1352-1360. Available at:, Accessed November 26, 2012. http://www.ncbi.nlm.nih.gov/pubmed/21655918, 10.1007/s10637-011-9699-0.
32. Oliner kS., Tang R., Anderson A., et al. Evaluation of MET pathway biomarkers in a phase II study of rilotumumab or placebo in combination with epirubicin, cisplatin, and capecitabine in patients with locally advanced or metastatic gastric or esophagogastric junction cancer. J Clin Oncol 2012, 30. [abstract 4005].
33. Turner N., Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010, 10(2):116-129. 10.1038/nrc2780.
34. Matsumoto K., Arao T., Hamaguchi T., et al. FGFR2 gene amplification and clinicopathological features in gastric cancer. Br J Cancer 2012, 106(4):727-732. 10.1038/bjc.2011.603.
35. Deng N., Goh L.K., Wang H., et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 2012, 61(5):673-684. 10.1136/gutjnl-2011-301839.
36. Ohtsu A., Shah M.A., Van Cutsem E., et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011, 29(30):3968-3976. Available at:, Accessed October 2, 2012. http://jco.ascopubs.org/content/29/30/3968.full.pdf, 10.1200/JCO.2011.36.2236.
37. Van Cutsem E., Yeh K.H., Bang Y.J., et al. Phase II trial of everolimus in previously treated patients with advanced gastric cancer: GRANITE-I. J Clin Oncol 2012, 30. [abstract LBA3].